As Regeneron Pharmaceuticals (REGN) Share Price Rose, Shareholder Genesee Valley Trust Company Cut Stake; Brenham Capital Management LP Position in Diamondback Energy (FANG) Upped by $9.70 Million as Stock Price Declined

January 14, 2018 - By Linda Rogers

Brenham Capital Management Lp increased its stake in Diamondback Energy Inc (FANG) by 8.7% based on its latest 2017Q3 regulatory filing with the SEC. Brenham Capital Management Lp bought 100,000 shares as the company’s stock declined 4.19% while stock markets rallied. The institutional investor held 1.25 million shares of the energy company at the end of 2017Q3, valued at $122.45 million, up from 1.15 million at the end of the previous reported quarter. Brenham Capital Management Lp who had been investing in Diamondback Energy Inc for a number of months, seems to be bullish on the $12.78 billion market cap company. The stock increased 0.18% or $0.24 during the last trading session, reaching $130.14. About 1.03M shares traded. Diamondback Energy, Inc. (NASDAQ:FANG) has risen 18.62% since January 14, 2017 and is uptrending. It has outperformed by 1.92% the S&P500.




Genesee Valley Trust Company decreased its stake in Regeneron Pharmaceuticals Inc (REGN) by 18.13% based on its latest 2017Q3 regulatory filing with the SEC. Genesee Valley Trust Company sold 960 shares as the company’s stock rose 21.24% with the market. The institutional investor held 4,335 shares of the health care company at the end of 2017Q3, valued at $1.94 million, down from 5,295 at the end of the previous reported quarter. Genesee Valley Trust Company who had been investing in Regeneron Pharmaceuticals Inc for a number of months, seems to be less bullish one the $39.22 billion market cap company. The stock decreased 0.35% or $1.3 during the last trading session, reaching $366.96. About 830,679 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since January 14, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

Among 38 analysts covering Diamondback Energy (NASDAQ:FANG), 34 have Buy rating, 0 Sell and 4 Hold. Therefore 89% are positive. Diamondback Energy had 101 analyst reports since July 21, 2015 according to SRatingsIntel. As per Monday, October 16, the company rating was maintained by SunTrust. On Wednesday, August 2 the stock rating was maintained by Williams Capital Group with “Hold”. The firm earned “Overweight” rating on Thursday, July 14 by Morgan Stanley. Roth Capital maintained it with “Buy” rating and $13000 target in Thursday, July 27 report. The firm has “Buy” rating given on Thursday, October 26 by Northland Capital. The firm has “Buy” rating given on Monday, December 11 by Northland Capital. On Tuesday, November 14 the stock rating was maintained by BMO Capital Markets with “Buy”. Credit Suisse initiated Diamondback Energy, Inc. (NASDAQ:FANG) on Monday, December 11 with “Buy” rating. As per Monday, October 10, the company rating was maintained by Williams Capital Group. The firm has “Buy” rating by Topeka Capital Markets given on Wednesday, January 13.

Since August 30, 2017, it had 0 insider purchases, and 10 sales for $2.17 million activity. Another trade for 5,000 shares valued at $559,142 was sold by Molnar Paul. Hollis Michael L. sold $210,000 worth of stock. $44,710 worth of stock was sold by Van’t Hof Matthew Kaes on Tuesday, December 12. 4,000 shares were sold by Pantermuehl Russell, worth $387,564 on Wednesday, September 20.

Investors sentiment increased to 1.53 in Q3 2017. Its up 0.32, from 1.21 in 2017Q2. It increased, as 43 investors sold FANG shares while 92 reduced holdings. 64 funds opened positions while 143 raised stakes. 104.84 million shares or 6.40% more from 98.54 million shares in 2017Q2 were reported. Travelers Inc invested in 0.45% or 7,439 shares. Avalon Advsrs Ltd Company owns 11,125 shares. Bessemer Gru invested 0.01% in Diamondback Energy, Inc. (NASDAQ:FANG). Moreover, Price T Rowe Associates Md has 0.05% invested in Diamondback Energy, Inc. (NASDAQ:FANG). British Columbia Mngmt Corp owns 113,612 shares. Virginia Retirement Et Al holds 0.01% or 11,277 shares. Moreover, Kbc Nv has 0.01% invested in Diamondback Energy, Inc. (NASDAQ:FANG) for 9,545 shares. Commerzbank Aktiengesellschaft Fi owns 94,100 shares. Caisse De Depot Et Placement Du Quebec has 0% invested in Diamondback Energy, Inc. (NASDAQ:FANG). Harvey Capital Mngmt Inc, Florida-based fund reported 6,000 shares. 74 are held by Fred Alger Inc. The New York-based Boothbay Fund Ltd has invested 0.16% in Diamondback Energy, Inc. (NASDAQ:FANG). Tennessee-based First Mercantile Trust has invested 0.07% in Diamondback Energy, Inc. (NASDAQ:FANG). Connor Clark & Lunn Inv Mgmt Limited holds 0.25% or 426,568 shares in its portfolio. Deutsche National Bank & Trust Ag reported 1.13 million shares.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.21, from 1.38 in 2017Q2. It dived, as 56 investors sold REGN shares while 165 reduced holdings. 71 funds opened positions while 187 raised stakes. 73.70 million shares or 3.04% more from 71.53 million shares in 2017Q2 were reported. Huntington Comml Bank reported 139 shares. Dekabank Deutsche Girozentrale invested in 70,119 shares or 0.26% of the stock. Fifth Third Fincl Bank stated it has 369 shares or 0% of all its holdings. Ls Inv Advsrs Ltd Liability Company has 2,107 shares for 0.06% of their portfolio. Janney Montgomery Scott Ltd Liability Corp holds 4,715 shares or 0.02% of its portfolio. Sumitomo Mitsui Asset Management Ltd holds 0.04% or 6,066 shares. Stifel Fin Corp has 87,259 shares. Savings Bank Of Montreal Can invested 0.02% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Rock Springs Cap Mgmt Limited Partnership has 16,000 shares. Pitcairn invested in 0.09% or 1,811 shares. Loring Wolcott Coolidge Fiduciary Advisors Ltd Liability Partnership Ma invested 0.01% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Bbva Compass Fincl Bank Inc holds 13,539 shares or 0.4% of its portfolio. Btim holds 1,050 shares or 0.01% of its portfolio. Fmr Limited Liability Company reported 6.99 million shares. Jpmorgan Chase And invested 0.03% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Genesee Valley Trust Company, which manages about $244.74M US Long portfolio, upped its stake in O’reilly Automotive Inc New Com (NASDAQ:ORLY) by 1,515 shares to 8,446 shares, valued at $1.82 million in 2017Q3, according to the filing. It also increased its holding in United Technologies Corp (NYSE:UTX) by 4,198 shares in the quarter, for a total of 8,534 shares, and has risen its stake in Microsoft Corporation (NASDAQ:MSFT).

Among 31 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 17 Hold. Therefore 42% are positive. Regeneron Pharmaceuticals Inc. had 104 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Buy” rating by BTIG Research given on Friday, December 16. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Buy” rating by Piper Jaffray on Tuesday, June 20. The firm has “Hold” rating given on Wednesday, January 27 by Canaccord Genuity. As per Friday, May 5, the company rating was upgraded by Canaccord Genuity. As per Thursday, November 9, the company rating was maintained by SunTrust. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Underweight” rating given on Friday, October 20 by Barclays Capital. Chardan Capital Markets downgraded the shares of REGN in report on Monday, August 31 to “Neutral” rating. On Friday, August 4 the stock rating was maintained by UBS with “Buy”. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Market Perform” rating by Wells Fargo on Wednesday, April 20. The company was maintained on Thursday, September 7 by Robert W. Baird.

Analysts await Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings on February, 8. They expect $4.18 EPS, up 90.87% or $1.99 from last year’s $2.19 per share. REGN’s profit will be $446.80M for 21.95 P/E if the $4.18 EPS becomes a reality. After $3.32 actual EPS reported by Regeneron Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 25.90% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: